Thursday, March 20, 2014 1:46:38 PM
Teva Copaxone Patent Reissue Yet Another Defense Strategy
2014-03-20 17:28:17.312 GMT
BI LITI NOAM LITI
Teva asked the U.S. Patent and Trademark Office to consider
reissuing the '808 patent that was invalidated in the Copaxone
litigation against Sandoz, Momenta, Mylan and Natco. Teva has
submitted new claims, amending the indefinite language objected
to by the Federal Circuit. If the patent authorities concur, the
reissue will have the same September 2015 expiry as the original
'808 patent. Teva can then file new litigation against generic
challengers.
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM